

# Lung Cancer: Non-Small Cell Lung Cancer (NSCLC) Pathways

Patient Name: \_\_\_\_\_

Date of Birth: \_\_\_\_\_

Member Number: \_\_\_\_\_

Treatment Start Date: \_\_\_\_\_

Pathology: \_\_\_\_\_

Stage: \_\_\_\_\_

Line of Therapy:  Neoadjuvant/Pre-Op  Adjuvant/Post-Op  
 1<sup>st</sup> Line  2<sup>nd</sup> Line  3<sup>rd</sup> Line  3<sup>rd</sup> Line+  Maintenance

ECOG Performance Status: \_\_\_\_\_ ICD-10 Code: \_\_\_\_\_

**Biomarkers/Characteristics:** (Select all that apply)

ALK:  Positive  Negative  Not reported

BRAF:  V600E Mutation  V600K Mutation  Wild type  Not reported

EGFR:  Mutation  Wild type  Not reported

PD-L1 expression:  1% to 49%  ≥50%  Negative  Not reported

T790M mutation:  Positive  Negative  Not reported

RET gene rearrangement:  Absent  Present  Not reported

MET amplification:  Positive  Negative  Not reported

Microsatellite instability:  dMMR/MSI-H  MSI-L  Not reported

ROS1 rearrangement:  Positive  Negative  Not reported

## Neoadjuvant/Preoperative/Induction Therapy or Adjuvant/Definitive Therapy

Cisplatin and etoposide (Toposar) with concurrent XRT

Paclitaxel and carboplatin with concurrent XRT

## Adjuvant Therapy

Carboplatin and paclitaxel

Cisplatin and gemcitabine (Gemzar)

Cisplatin and vinorelbine (Navelbine)

## Metastatic Disease | Squamous | ALK/EGFR Negative (ROS Negative or Unknown) | TPS ≥ 50% | First Line of Therapy (1st Line) | ECOG PS: 0-2

Pembrolizumab (Keytruda)\*

## Metastatic Disease | Squamous | TPS < 50% | First Line of Therapy (1st Line) | ECOG PS: 0-2

Pembrolizumab (Keytruda)\*, carboplatin, and paclitaxel

## Metastatic Disease | Nonsquamous | ALK/EGFR Negative (ROS1 Negative or Unknown) | TPS ≥ 50% | First Line of Therapy (1st Line) | ECOG PS: 0-2

Pembrolizumab (Keytruda)\*

## Metastatic Disease | Nonsquamous | ALK/EGFR Negative (ROS1 Negative or Unknown) | TPS < 50% | First Line of Therapy (1st Line) | ECOG PS: 0-2

Carboplatin†, pemetrexed (Alimta), and pembrolizumab (Keytruda)

## Metastatic Disease | Squamous or Nonsquamous | Immunotherapy-Ineligible | First Line of Therapy (1st Line) | ECOG PS: 0-2

Carboplatin† and paclitaxel

Carboplatin, paclitaxel, and bevacizumab (Avastin) (NON-SQUAMOUS ONLY)

Cisplatin† and gemcitabine (Gemzar)

Cisplatin† and pemetrexed (Alimta) (NON-SQUAMOUS ONLY)

\* Administered at a dose of 2 mg/kg (up to a maximum of 200 mg)

† In the setting of recurrent/metastatic NSCLC, a substitution of carboplatin for cisplatin (or vice-versa) will be considered a pathway option.

‡ Eligible only if immunotherapy alone was administered as first line treatment. Ineligible if chemotherapy was used in the first line setting.

**Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars of reference products listed are considered "on pathway." However, reimbursement for biosimilar products may be impacted by health plan specific formularies, medical policy and preferred product rules.**



8600 West Bryn Mawr Avenue  
South Tower - Suite 800 Chicago, IL 60631  
[www.aimspecialtyhealth.com](http://www.aimspecialtyhealth.com)

Last review: 12/3/2019 | Effective date: 2/4/2019

Appropriate.Safe.Affordable

© 2020 AIM Specialty Health  
9017-0220

# Lung Cancer: Non-Small Cell Lung Cancer (NSCLC) Pathways (continued)

## Metastatic Disease | Non-Squamous | Maintenance | ECOG PS: 0-2

- Continuation bevacizumab (Avastin)
- Continuation pemetrexed (Alimta)
- Pembrolizumab (Keytruda)\* and pemetrexed (Alimta) (if previously treated with carboplatin†, pemetrexed, and pembrolizumab)
- Switch pemetrexed (Alimta)

## Metastatic Disease | Second or Subsequent Lines of Therapy (2<sup>nd</sup> Line+) | ECOG PS: 0-2

- Atezolizumab (Tecentriq) (if no prior checkpoint inhibitors)
- Nivolumab (Opdivo) (if no prior checkpoint inhibitors)
- Carboplatin‡ and paclitaxel‡
- Carboplatin‡ and gemcitabine (Gemzar)‡
- Carboplatin‡ and pemetrexed (Alimta)‡

## Metastatic Disease | ALK Positive | First Line of Therapy (1<sup>st</sup> Line)

- Alectinib (Alecensa)

## Metastatic Disease | EGFR Positive | First Line of Therapy (1<sup>st</sup> Line)

- Osimertinib (Tagrisso)

## Metastatic Disease | ALK or EGFR Positive | Second or Subsequent Lines of Therapy (2<sup>nd</sup> Line+) | ECOG PS: 0-2

- Carboplatin† and paclitaxel
- Cisplatin† and gemcitabine (Gemzar)
- Cisplatin† and pemetrexed (Alimta)

## Metastatic Disease | EGFR Positive | ECOG PS: 3-4

- Erlotinib (Tarceva)

\* Administered at a dose of 2 mg/kg (up to a maximum of 200 mg)

† In the setting of recurrent/metastatic NSCLC, a substitution of carboplatin for cisplatin (or vice-versa) will be considered a pathway option.

‡ Eligible only if immunotherapy alone was administered as first line treatment. Ineligible if chemotherapy was used in the first line setting.

**Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars of reference products listed are considered "on pathway." However, reimbursement for biosimilar products may be impacted by health plan specific formularies, medical policy and preferred product rules.**

